Previous close | 66.98 |
Open | 67.34 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 67.34 - 67.34 |
52-week range | 65.30 - 80.04 |
Volume | |
Avg. volume | 47 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 25 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024. If you do not want to learn about the global healthcare market, head straight to the 5 Biggest Health Care Companies in Australia, 2024. In 2024, Australia’s healthcare landscape will be dominated by a myriad of […]